Literature DB >> 438963

Pharmacokinetics of topically applied pilocarpine in the albino rabbit eye.

M C Makoid, J R Robinson.   

Abstract

The temporal and spatial pattern of [3H]-pilocarpine nitrate distribution in the albino rabbit eye following topical administration was determined. A four-compartment caternary chain model describing this disposition corresponds to the precorneal area, the cornea, the aqueous humor, and the lens and vitreous. Simultaneous computer fitting of data from tissue corresponding to some compartments in the model supported the proposed model. Additional support was provided by the excellent correlation between predicted and observed values in multiple-dosing studies. Several important aspects of ocular drug disposition are evident from the model. The extensive parallel elimination at the absorption site gives rise to an apparent absorption rate constant that is one to two orders of magnitude larger than the true absorption rate constant. In addition, aqueous flow accounts for most of the drug removal. Thus, major effects on absorption and elimination, independent of the drug structure, suggest the possibility of similar pharmacokinetics for vastly different drugs.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 438963     DOI: 10.1002/jps.2600680411

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  18 in total

1.  General Pharmacokinetic Model for Topically Administered Ocular Drug Dosage Forms.

Authors:  Feng Deng; Veli-Pekka Ranta; Heidi Kidron; Arto Urtti
Journal:  Pharm Res       Date:  2016-07-18       Impact factor: 4.200

Review 2.  Ocular drug delivery. Pharmacokinetic considerations.

Authors:  R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

3.  Application of Mechanistic Ocular Absorption Modeling and Simulation to Understand the Impact of Formulation Properties on Ophthalmic Bioavailability in Rabbits: a Case Study Using Dexamethasone Suspension.

Authors:  Maxime Le Merdy; Jianghong Fan; Michael B Bolger; Viera Lukacova; Jessica Spires; Eleftheria Tsakalozou; Vikram Patel; Lin Xu; Sharron Stewart; Ashok Chockalingam; Suresh Narayanasamy; Rodney Rouse; Murali Matta; Andrew Babiskin; Darby Kozak; Stephanie Choi; Lei Zhang; Robert Lionberger; Liang Zhao
Journal:  AAPS J       Date:  2019-05-20       Impact factor: 4.009

Review 4.  A comprehensive insight on ocular pharmacokinetics.

Authors:  Vibhuti Agrahari; Abhirup Mandal; Vivek Agrahari; Hoang M Trinh; Mary Joseph; Animikh Ray; Hicheme Hadji; Ranjana Mitra; Dhananjay Pal; Ashim K Mitra
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

5.  A physiologically based pharmacokinetic model for the intraocular distribution of pilocarpine in rabbits.

Authors:  S C Miller; K J Himmelstein; T F Patton
Journal:  J Pharmacokinet Biopharm       Date:  1981-12

6.  Characterization of ocular pharmacokinetics of beta-blockers using a diffusion model after instillation.

Authors:  K Yamamura; H Sasaki; M Nakashima; M Ichikawa; T Mukai; K Nishida; J Nakamura
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

7.  Evidence for site-specific absorption of a novel ACE inhibitor.

Authors:  G M Grass; W T Morehead
Journal:  Pharm Res       Date:  1989-09       Impact factor: 4.200

8.  Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids.

Authors:  Sudharshan Hariharan; Sriram Gunda; Gyan P Mishra; Dhananjay Pal; Ashim K Mitra
Journal:  Pharm Res       Date:  2008-10-29       Impact factor: 4.200

9.  Ocular pharmacokinetic models of clonidine-3H hydrochloride.

Authors:  C H Chiang; R D Schoenwald
Journal:  J Pharmacokinet Biopharm       Date:  1986-04

10.  Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections.

Authors:  Suresh Katragadda; Sriram Gunda; Sudharshan Hariharan; Ashim K Mitra
Journal:  Int J Pharm       Date:  2008-03-22       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.